Technical Analysis for MRKR - Marker Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MRKR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 17 | Outside Day | Range Expansion | 0.00% |
| Jan 17 | Wide Bands | Range Expansion | 0.00% |
| Jan 16 | NR7 | Range Contraction | -0.17% |
| Jan 16 | Wide Bands | Range Expansion | -0.17% |
| Jan 15 | 20 DMA Support | Bullish | 3.88% |
| Jan 15 | Wide Bands | Range Expansion | 3.88% |
| Jan 14 | Outside Day | Range Expansion | 0.17% |
| Jan 14 | Wide Bands | Range Expansion | 0.17% |
| Jan 11 | NR7 | Range Contraction | -0.34% |
| Jan 11 | Inside Day | Range Contraction | -0.34% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-21
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRKR news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 13.55 |
| 52 Week Low | 2.58 |
| Average Volume | 229,635 |
| 200-Day Moving Average | 6.9348 |
| 50-Day Moving Average | 6.4284 |
| 20-Day Moving Average | 5.523 |
| 10-Day Moving Average | 6.107 |
| Average True Range | 0.5509 |
| ADX | 16.74 |
| +DI | 21.9927 |
| -DI | 22.4219 |
| Chandelier Exit (Long, 3 ATRs ) | 5.4473 |
| Chandelier Exit (Short, 3 ATRs ) | 5.8327 |
| Upper Bollinger Band | 7.1389 |
| Lower Bollinger Band | 3.9071 |
| Percent B (%b) | 0.61 |
| BandWidth | 58.5153 |
| MACD Line | -0.1212 |
| MACD Signal Line | -0.1959 |
| MACD Histogram | 0.0747 |
| Fundamentals | Value |
|---|---|
| Market Cap | 59.83 Million |
| Num Shares | 10.2 Million |
| EPS | -1.02 |
| Price-to-Earnings (P/E) Ratio | -5.77 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 3.74 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.49 | ||||
| Resistance 3 (R3) | 6.50 | 6.31 | 6.39 | ||
| Resistance 2 (R2) | 6.31 | 6.16 | 6.31 | 6.36 | |
| Resistance 1 (R1) | 6.10 | 6.06 | 6.01 | 6.09 | 6.32 |
| Pivot Point | 5.91 | 5.91 | 5.86 | 5.91 | 5.91 |
| Support 1 (S1) | 5.70 | 5.76 | 5.61 | 5.69 | 5.46 |
| Support 2 (S2) | 5.51 | 5.66 | 5.51 | 5.42 | |
| Support 3 (S3) | 5.30 | 5.51 | 5.39 | ||
| Support 4 (S4) | 5.29 |
